tiprankstipranks
Trending News
More News >
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Advertisement

Astria Therapeutics (ATXS) AI Stock Analysis

Compare
1,131 Followers

Top Page

ATXS

Astria Therapeutics

(NASDAQ:ATXS)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
Astria Therapeutics' stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.
Positive Factors
Strong Balance Sheet
A strong balance sheet with low leverage and high equity provides financial stability, allowing Astria Therapeutics to fund its R&D efforts without immediate revenue pressure.
Scientific Expertise
The company's focus on scientific expertise ensures a robust pipeline of innovative drug candidates, positioning it well to address unmet medical needs in rare diseases.
Partnership Revenue Model
Astria's revenue model, based on partnerships, provides potential for upfront and milestone payments, offering financial support and market access for its drug candidates.
Negative Factors
Pre-Revenue Stage
Being in a pre-revenue stage with no current income stream increases financial risk, as the company relies heavily on external funding to sustain operations and development.
Increasing Net Losses
Rising net losses reflect the high costs associated with drug development, which could strain financial resources and delay profitability unless offset by successful product launches.
Negative Cash Flow
Negative cash flow indicates challenges in sustaining operations without external financing, highlighting the need for successful partnerships or product approvals to improve cash generation.

Astria Therapeutics (ATXS) vs. SPDR S&P 500 ETF (SPY)

Astria Therapeutics Business Overview & Revenue Model

Company DescriptionAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
How the Company Makes MoneyAstria Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and potential royalties on sales of successfully developed drugs. Additionally, Astria Therapeutics may receive funding through grants and research collaborations. The company's revenue model typically involves significant investment in research and development, with potential returns materializing upon regulatory approval and market launch of its therapies.

Astria Therapeutics Financial Statement Overview

Summary
Astria Therapeutics is in a pre-revenue stage with increasing net losses. A robust balance sheet with low leverage and high equity provides financial stability, but the absence of revenue and consistent cash outflows present significant financial risks.
Income Statement
10
Very Negative
Astria Therapeutics has consistently reported zero revenue over the years, reflecting its pre-revenue stage typical for biotechnology firms. The net losses have increased, with the net income showing a decline from -$26.2M in 2019 to -$94.3M in 2024. The lack of revenue and increasing losses limit the assessment of profitability and growth metrics, resulting in a lower score.
Balance Sheet
70
Positive
The company maintains a strong equity position with a high equity ratio, indicating a solid financial structure. The debt-to-equity ratio remains low due to minimal debt, demonstrating conservative leverage. However, the lack of revenue generation could pose future financial risks if cash reserves diminish without revenue inflow.
Cash Flow
50
Neutral
Astria Therapeutics has negative operating cash flow, which is expected in a pre-revenue biotech company. Despite the negative free cash flow, the company has managed cash inflow through financing activities, maintaining adequate cash reserves. The operating cash flow to net income ratio suggests challenges in generating cash relative to reported net losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-131.42M-94.26M-83.03M-53.50M-194.98M-37.44M
Net Income-116.92M-94.26M-72.89M-51.83M-194.91M-37.30M
Balance Sheet
Total Assets281.92M342.36M254.67M230.63M127.51M47.46M
Cash, Cash Equivalents and Short-Term Investments259.18M328.13M246.53M226.44M125.51M44.93M
Total Debt4.77M5.35M329.00K939.00K365.00K1.05M
Total Liabilities21.41M23.10M11.55M9.42M5.20M6.79M
Stockholders Equity260.51M319.26M243.12M221.22M122.31M40.67M
Cash Flow
Free Cash Flow-116.01M-81.54M-68.47M-43.62M-30.17M-32.52M
Operating Cash Flow-115.40M-81.21M-68.44M-43.53M-30.15M-32.48M
Investing Cash Flow89.05M-191.86M135.05M-167.13M-12.55M6.30M
Financing Cash Flow15.30M157.20M88.40M144.72M104.28M40.86M

Astria Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.30
Price Trends
50DMA
6.87
Positive
100DMA
6.06
Positive
200DMA
6.46
Positive
Market Momentum
MACD
0.15
Positive
RSI
53.21
Neutral
STOCH
37.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXS, the sentiment is Positive. The current price of 7.3 is above the 20-day moving average (MA) of 7.26, above the 50-day MA of 6.87, and above the 200-day MA of 6.46, indicating a bullish trend. The MACD of 0.15 indicates Positive momentum. The RSI at 53.21 is Neutral, neither overbought nor oversold. The STOCH value of 37.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXS.

Astria Therapeutics Risk Analysis

Astria Therapeutics disclosed 72 risk factors in its most recent earnings report. Astria Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Astria Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
641.68M-8.32-100.00%-25.75%
52
Neutral
659.05M-4.73-97.15%54.85%
47
Neutral
232.52M-1.8223.24%
44
Neutral
$410.28M-38.49%11.81%
42
Neutral
274.79M-3.7963.92%
33
Underperform
304.12M-8.0760.29%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ATXS
Astria Therapeutics
7.30
-3.71
-33.70%
AUTL
Autolus Therapeutics
1.56
-2.07
-57.02%
ADCT
ADC Therapeutics
3.65
0.50
15.87%
FDMT
4D Molecular Therapeutics
8.39
-2.42
-22.39%
PRTC
PureTech Health
16.90
-3.72
-18.04%
GLUE
Monte Rosa Therapeutics
7.49
2.19
41.32%

Astria Therapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Astria Therapeutics Unveils Phase 3 Trial for Navenibart
Positive
Jan 13, 2025

Astria Therapeutics has announced the design of the ALPHA-ORBIT Phase 3 clinical trial for navenibart, a treatment for hereditary angioedema, which will feature both every 3- and 6-month treatment arms. This trial aims to support global registration and is expected to initiate in Q1 2025. The company is pioneering flexible dosing options to potentially make navenibart a market-leading choice for HAE therapy, and the trial design incorporates feedback from regulatory authorities and collaboration with patients and physicians.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 24, 2025